Assumptions underlying these estimates are detailed in section of this article. g The published report did not provide the number of major extracranial bleeds that were fatal and nonfatal; therefore, we imputed values for the number of fatal and nonfatal major extracranial bleeds to estimate the relative risk for nonfatal major extracranial bleeds. Assumptions underlying these estimates are detailed in section of this article. h Rate of nonfatal major extracranial bleeding on warfarin is from observational cohorts of patients receiving adjusted-dose VKA therapy (median, 1.3%/y). i Based on rate of systemic embolism on aspirin of per patient-y reported in the IPD meta-analysis of warfarin vs aspirin by van Walraven et al and a relative risk for systemic embolism of with VKA vs aspirin ( Table ). e554S Antithrombotic Therapy for Atrial Fibrillation (Continued) Table [ Section Should Dabigatran mg bid Rather Than VKAs Be Used in Patients With AF? Quality Assessment Summary of Findings Risk of Bias Inconsistency Indirectness Imprecision Publication Bias Study Event Rates (%) Relative Effect CI) Estimation of Absolute Effects Time Frame No. 